Ketorolac Tromethamine
Leukemia, Chronic Myelogenous (CML)
City of Hope Medical CenterPhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Leukemia, Chronic Myelogenous (CML) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FENTANYL City of Hope Medical Center | Phase 1/2 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE City of Hope Medical Center | Phase 1/2 | B |
Benadryl City of Hope Medical Center | Phase 1/2 | B |
HYDROMORPHON City of Hope Medical Center | Phase 1/2 | B |
Keyhole Limpet Hemocyanin National Cancer Institute (NCI) | Phase 1/2 | CCC |
wt1 peptide-pulsed dendritic cells National Cancer Institute (NCI) | Phase 1/2 | CCC |
LIPOPOLYSACCHARIDE National Cancer Institute (NCI) | Phase 1/2 | CCC |
il-4 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Same molecule, other indications
Ketorolac Tromethamine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →